Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
Journal of Hematology & Oncology, 05/07/2012Galili N et al.
The authors have shown that an ezatiostat response profile contains two miRNAs that regulate expression of genes known to be implicated in myelodysplastic syndrome (MDS) disease pathology. Remarkably, pathway analysis of the response profile revealed that the genes comprising the jun–N–terminal kinase/c–Jun molecular pathway, which is known to be activated by ezatiostat, are under–expressed in patients who respond and over–expressed in patients who were non–responders to the drug, suggesting that both the biology of the disease and the molecular mechanism of action of the drug are positively correlated.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.